Azurity

8 products tracked · names used in filings: Azurity, Azurity Pharmaceuticals Ireland Ltd.

Upcoming milestones

No upcoming milestones listed.

Recent milestones

Fri 25 Sep 2026🇺🇸 FDA approval

FDA approves Lamlique (lamotrigine hemifumarate): new active ingredient

Azurity; NDA221109; New active ingredient; suspension · source

Tue 16 Jun 2026🇺🇸 FDA approval

FDA approves Aprepitant (aprepitant): new formulation or manufacturer

Azurity; NDA218754; New formulation or manufacturer; emulsion · source

Thu 23 Oct 2025🇺🇸 FDA approval

FDA approves Javadin (clonidine hydrochloride): new dosage form

Azurity; NDA220256; New dosage form; solution · source

Thu 16 Oct 2025🇺🇸 FDA approval

FDA approves Ferabright (ferumoxytol): new indication (separate nda)

Azurity; NDA219868; New indication (separate NDA); solution · source

Products

ProductStatusApproved
🇺🇸Lamlique
lamotrigine hemifumarate		Approved2026-09-25
🇺🇸Aprepitant
aprepitant		Approved2026-06-16
🇺🇸Javadin
clonidine hydrochloride		Approved2025-10-23
🇺🇸Ferabright
ferumoxytol		Approved2025-10-16
🇪🇺Brimica Genuair
aclidinium;formoterol fumarate dihydrate		Authorised2014-11-19
🇪🇺Duaklir Genuair
aclidinium bromide;formoterol		Authorised2014-11-19
🇪🇺Bretaris Genuair
aclidinium bromide		Authorised2012-07-20
🇪🇺Eklira Genuair
aclidinium bromide		Authorised2012-07-20

Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.